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Abstract 
 
Human mast cells are potent effector cells in host defense mechanisms of innate and acquired 
immunity, including inflammatory diseases such as asthma and atherosclerosis. Mast cells originate 
from pluripotent hematopoietic progenitors in the bone marrow. Activation of mast cells by 
different stimuli triggers the release of a large range of mediators, including de novo synthesized 
eicosanoids which are highly biologically active lipid mediators. Eicosanoids derive from the 
omega-6 polyunsaturated fatty acid, arachidonic acid (AA) which is usually esterified at the sn-2 
position of membrane phospholipids. Human mast cells actually contain a significant amount, if not 
even the majority, of arachidonic acid incorporated in triglycerides (TGs) which are stored in their 
cytoplasmic lipid droplets. While the liberation of arachidonic acid from phospholipids by 
phospholipase family members is well-studied, the hydrolysis of AA-containing triglycerides for 
the use of eicosanoid biosynthesis has not been studied until very recently.  
 
The aim of this study is the elucidation of molecular mechanisms involved in the generation of 
eicosanoids in human mast cells with particular emphasis on lipid droplets as a source and/or site of 
lipid mediator biogenesis. The major prostanoid released by activated mast cells is the eicosanoid 
prostaglandin D2 (PGD2). The putative enzymes involved in arachidonic acid liberation from 
triglycerides included (hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL). We 
were also interested about hematopoietic prostaglandin D synthase (HPGDS), the key enzyme in the 
production of D and J series of prostanoids. The methods used included cell culture work and 
siRNA transfections; basic molecular biological methods such as RNA isolation, cDNA synthesis 
and qPCR; basic molecular biochemical methods including immunoblotting and ELISA; as well as 
immunofluorescence staining.  
 
The increase in the amount of PGD2 released from mast cells sensitized with human IgE (1µg/ml) 
and activated by polyclonal rabbit anti-human IgE (1µg/ml) was immediate and most prominent 
after one hour of activation, and slowly decreased to basal levels at 48h post-activation. siRNA 
transfection affected the amount of enzyme DNA in mast cells and the amount of PGD2 released. 
HSL, ATGL and HSL+ATGL double knockdown all reduced the amount of PGD2 released in acute 
(5 to 30 minutes) term activation compared to control cells. However, no significant changes were 
observed in the mRNA expression levels of ATGL, HSL, CGI-58, HPGDS or COX-1 under mast 
cell activation. The only significant changes in mRNA expression levels were observed with COX-
2.  The relative expression of HPGDS increased in IgE treated mast cells compared to control 
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treated cells and the expression was even greater in mast cells treated also with αIgE. Both ATGL 
and HPGDS were recognized throughout the cytosolic area in the non-activated Ctrl cells. Although 
HPGDS located also in the circumference of mast cells, no clear localization of HPGDS was 
observed in the circumference of mast cell lipid droplets as expected based on previous findings 
about the localizations within the lipid droplets of the enzymes involved in the synthesis of 
leukotrienes and prostaglandins.
1
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Tiivistelmä 
 
Syöttösolut saavat alkunsa hematopoieettisista CD34 -pinta-antigeenille positiivisista esiasteista. 
Syöttösolut ovat osa kehon synnynnäistä ja hankittua immuunipuolustusjärjestelmää ja ne tunnetaan 
parhaiten klassisten allergiaoireiden aiheuttajina. Syöttösolut osallistuvat kuitenkin myös 
sepelvaltimotaudin, astman ja aineenvaihduntasairauksien kehittymiseen. Syöttösolujen aktivaatio 
johtaa erilaisten solu- ja lipidivälittäjäaineiden kuten eikosanoidien synteesiin (de novo) ja 
vapautumiseen. Eikosanoidit ovat biologisesti aktiivisia kudoshormoneita ja lipidivälittäjäaineita, 
joiden tiedetään muodostuvan kun monityydyttymätön omega-6 rasvahappo, arakidonihappo 
hydrolysoidaan solukalvorakenteiden fosfolipideistä, yleensä asemasta 2 (Sn2).  Arakidonihapon 
vapautumista fosfolipideistä on tutkittu paljon ja vapautumisreitit ovat hyvin tunnettuja. Sen sijaan 
eikosanoidien biosynteesin mekanismia syöttösolujen lipidipartikkeleiden triglyserideistä ei ole 
tutkittu aiemmin. Ihmisten syöttösolujen sytosolissa sijaitsevien lipidipartikkeleiden ytimien 
triglyserideissä tiedetään kuitenkin olevan runsaasti arakidonihappoa. 
 
Tämän tutkielman tarkoitus on perehtyä ihmisen syöttösolujen eikosanoidien biosynteesin 
molekyylitason mekanismeihin. Erityisesti mielenkiinnon kohteena ovat syöttösolut 
lipidivälittäjäaineiden muodostuspaikkana. Arakidonihapon vapautumisessa triglyserideistä ovat 
olennaisessa osassa hormoni-sensitiivinen lipaasi (HSL) ja rasvakudoksen triglyseridilipaasi 
(ATGL).  Syöttösolujen pääasiallisesti vapauttama eikosanoidi on prostaglandiini D2 (PGD2). 
Hematopoieettinen prostaglandiini D syntaasi (HPGDS) on tärkeä tämän D- sarjan prostaglandiinin 
entsymaattisessa muodostuksessa. Tutkimuksessa käytettiin soluviljelytöitä ja siRNA transfektiota 
syöttösolujen entsyymigeenien hiljentämiseen; RNA:n eristystä, cDNA synteesiä, qPCR:ää 
entsyymiproteiinien sekvenssin monistamiseksi; immunodetektiota entsyymiproteiinien ja ELISAa 
muodostuvan PGD2 määrän kvantitointiin; ja immunofluoresenssivärjäyksiä lipidipartikkeliden 
osoittamiseen ja entsyymiproteiinien sijainnin määrittämiseen syöttösoluissa.  
 
Syöttösolujen herkistäminen IgE:llä (1µg/ml) ja aktivointi polyklonaalisella αIgE:llä (1µg/ml) sai 
aikaan vapautuvan PGD2:n määrän nopean ja huomattavan suurenemisen. Vapautuvan PGD2:n 
määrän kasvu oli voimakkaimmillaan tunnin kuluttua aktivaatiosta ja palasi lähtötasolle 48 tuntia 
aktivaation jälkeen. siRNA-transfektio vaikutti entsyymi DNA:n ja vapautuvan PGD2:n määrään. 
HSL, ATGL ja HSL+ATGL hiljennykset alensivat vapautuvan PGD2 määrää kontrollisoluihin 
verrattuna akuutin (5-30 minuutin) aktivaation jälkeen.  mRNA-tasolla ei havaittu merkittäviä 
muutoksia ATGL, HSL, CGI-58, HPGDS tai COX-1 ekspressiossa aktivaation jälkeen. Ainoa 
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merkittävä muutos havaittiin COX-2- entsyymin mRNA-ekspressiossa. HPGDS:n suhteellinen 
ekspressio lisääntyi IgE:llä käsitellyissä syöttösoluissa kontrolleihin verrattuna, ja oli tätäkin 
voimakkaampaa myös αIgE:llä käsitellyissä soluissa. Immunofluoresenssivärjäyksissä vasta-aineet 
tunnistivat sekä ATGL että HPGDS ei-aktivoitujen kontrollisolujen sytosolissa. Vaikka HPGDS 
tunnistettiin myös solujen ulkoreunoilla, entsyymi ei sijoittunut erityisesti syöttösolujen 
lipidipartikkeleiden ympärille, vaikka näin oli syytä odottaa aiempien tutkimusten perusteella.
1
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Abbreviations* 
 
A 
 
AA = arachidonic acid 
 
ACSL = long chain acyl-CoA synthetase 
 
ATGL = adipose triglyceride lipase 
 
B 
 
BSA = bovine serum albumin 
 
C 
 
CGI-58 = a comparative gene identification-58 or α/β-Hydrolase Domain -Containing Protein 5, 
also known as 1-acylglycerol-3-phosphate O-acyltransferase ABHD5  
 
cAMP = cyclic adenosine monophosphate, cyclic AMP or 3'-5'-cyclic adenosine monophosphate 
 
COX = cyclooxygenase 1 and 2 also known as prostaglandin H synthase or PGHS 1 and 2 
 
cPLA2 = cytosolic phospholipase A2 
 
D 
 
DAG = diacylglycerol 
 
E 
 
EDTA = ethylenediaminetetraacetic acid 
 
ELISA = enzyme-linked immunosorbent assay 
 
G 
 
GAPDH = glyceraldehyde 3-phosphate dehydrogenase 
 
H 
 
HPGDS = hematopoietic prostaglandin D synthase a.k.a terminal hematopoietic prostaglandin D2 
synthase 
 
HSL = hormone-sensitive lipase 
 
K 
 
KIT = kit-ligand, KITL or KL also known as stem cell factor (SCF), a cytokine that binds to the c-
 7 
 
Kit receptor (CD117) 
 
L 
 
LD = lipid droplet a.k.a lipid body 
 
LPGDS = lipocalin-type prostaglandin D synthase 
 
LSDP5 = lipid storage droplet protein, also known as lipid droplet scaffold protein  
 
5-LO = arachidonate 5-lipoxygenase, 5-lipoxygenase 
 
15-LO (15-1) = 15-lipoxygenase-1 
 
M 
 
MC = mast cell 
 
MITF = microphthalmia-associated transcriptor factor, a basic-helix-loop-helix leucine zipper 
transcription factor 
 
N 
 
NEFA = non-esterified fatty acid 
 
P 
 
PGD2 = Prostaglandin D2 
 
PGH = Prostaglandin H 
 
PLIN1 = Perilipin, also known as lipid droplet-associated protein  
 
PLIN2 = perilipin 2, also known as Adipose differentiation-related protein, ADFP or adipophilin 
 
PKA = Protein kinase A 
 
Q 
 
qPCR = quantitative polymerase chain reaction 
 
R 
 
RasGRP4 = RAS guanyl releasing protein 4 
 
RT-PCR = reverse transcriptase polymerase chain reaction 
 
*The abbreviations used were selected because they are well-known or commonly used in scientific 
articles of related topics and on the other hand were as unambiguous as possible having no other 
meaning (in biology). 
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1 Introduction 
 
1.1 Mast cells 
 
 Human mast cells are present in almost all vascularized tissues including skin, mucosal tissue of 
lungs and digestive tract, arterial intima, mouth, nose and conjunctiva. They are most common at 
the sites exposed to the external environment. Mast cells (Fig. 1) are oval cells of approximately 10 
μm in size with densely packed and metachromatically staining granules. The number of mast cells 
in healthy individuals is quite stable, but pathologic conditions can disturb this homeostasis leading 
to mastocytosis i.e. the accumulation of mast cells and release of mast cell mediators.
2
 Disorders of 
mast cell proliferation are known, but the ability to study mast cells has been limited because 
mature mast cells can only be extracted 
from tissue sites –from lungs, skin, uterus 
and intestine
3
 and because of a lack of 
means to maintain human mast cells in long 
term cultures.
4
 
 
 
Figure 1: Human mast cells on their 5
th
 week 
of culture. The round nucleus stained blue is 
surrounded by lipid droplets of various sizes. (a) Neutral lipid droplets were visualized by ORO stainings or 
(b) by the fluorescent dye BODIPY493/503 ® in mast cells where lipid droplet formation was enhanced by 
exogenous treatment with AA:BSA -complexes (250 µM for 18 hours at +37°C). 
 
1.2 Origin, migration, development and differentiation of mast cells 
 
There are two mast cell phenotypes, the mucosal and the connective tissue type. The connective 
tissue type produces both tryptase and chymase (TC-MC), whereas mucosal mast cells (T-MC) 
express tryptase only. All mast cells originate from pluripotent hematopoietic progenitors in the 
bone marrow, circulate as mast cell progenitors (MCPs) and acquire their final maturity and develop 
their granules in the target tissues, where they ultimately reside.  Mast cell survival and maturation 
is guided by KITL, a ligand for c-Kit receptor expressed on the mast cell surface.
5
 KITL is a 
chemokine expressed by stromal mesenchymal cells
6,7
 and the only cytokine and adherence factor 
absolutely vital for the development of mature mast cells.
8
 Cell membrane bound KITL or its 
soluble isoforms are positively chemotactic for mast cells and their progenitors.
2
 Besides being a 
chemotactic factor, KITL also elicits cell to cell, and cell to substratum adhesion, facilitates cell 
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proliferation, differentiation and maturation.
2
  Binding of KITL to c- Kit receptor induces the 
homodimerization of two receptor monomers, thus facilitating their activation.
2,9
 Signalling 
downstream from c-Kit induces well-known pathways including phospholipases.
9
 Additional mast 
cell maturation and survival factors are interleukin 3 (IL-3), Th2-derived IL-4 and IL-9, and various 
other factors.
6,7
 
 
1.3 Mast cell mediators 
 
Mast cells are documented to play a major role in both innate and acquired immunity including 
inflammatory diseases such as allergy, intestinal disease and atherosclerosis as well as lifestyle or 
metabolic diseases.
10
 Mast cells are able to rapidly and selectively produce appropriate mediators 
for physiological and innate immune responses, they can enhance effector cell recruitment because 
of their location near blood vessels and they are able to modify immune responses against infectious 
agents in an antibody dependent manner.
3
 Mast cells can be activated by non-immunological stimuli 
(e.g. pollen, bacteria, virus, parasites, chemicals, radiation) or by immunological stimuli, including 
specific antigens or molecules, complement proteins or by other transmembrane stimuli.
11
 Three 
main classes of mediators are produced in mast cells: preformed granule-associated mediators such 
as vasoactive amine histamine and serine proteases; newly generated lipid mediators produced 
independently from above mentioned granules; and cytokines, chemokines and other growth 
factors.
1,3,12-14
 Mast cells express a large variety of cell surface receptors which enable a specific 
response to different stimuli via the release of these biologically active mediators. 
 
The best-studied signalling pathways of mast cells are those mediated either through high-affinity 
IgE receptor FcϵRI (Fcε receptor type I) which plays a classical role in acute hypersensitivity 
reactions, including asthma and other allergic disorders or those activated when calcium 
inonophores are added to the cells.
5
  IgE usually exists as a monomer. In the classical IgE/FcεRI 
pathway the binding of an antigen to IgE which is already tightly bound to FcεRI on mast cell 
surface, causes the pairing of two IgE-molecules. This pairing or crosslinking leads to aggregation 
of the FcεRIs, a rapid exocytosis of cytoplasmic secretory granules via a process termed 
‘degranulation’ and to concomitant release of mediators such as PGD2
15
 and generation of 
diacylglycerol (DAG),
8
 the substrate of hormone sensitive lipase (HSL). DAG generation has been 
associated to morphological changes taking place during mast cell activation.
8
 The cytoplasmic 
secretory organelles contain histamine and neutral serine proteases such as tryptase and chymase 
typical for mast cells,
1,16
 and they are responsible for the type I allergy a.k.a hypersensitivity or 
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classical allergy, although a ”T-helper cell 2 -type of response” and B-cell activation and switch to 
IgE isotype is also needed. In this condition the immune response targets against harmless or useful 
substances. 
 
Activation via another receptor called c-Kit also known as CD117 leads to formation of the de-novo 
synthesized eicosanoids including PGD2, thromboxane, platelet-activating factor, leukotriene (LT) 
B4 and leukotriene C4 (LTC4) which are all highly biologically active lipid mediators.
11
 Knowledge 
of the mechanisms for their secretion is incomplete, but all major mast cell lipid mediators are 
known to derive enzymatically from a common precursor, arachidonic acid (AA), an ω-6 
polyunsaturated fatty acid with 20 carbon atoms and double bonds at positions 5,8,11 and 14 
(5,8,11,14-all-cis-Eicosatetraenoic acid) for which reason they are called ‘eicosanoids’. The 
arachidonic acid can be obtained either from the diet or it can be enzymatically derived from 
linoleic acid 18:2(n-6).
17
 Newly formed eicosanoids are lipid soluble and can move out from the 
cell and affect neighboring cells, diffuse to the extracellular space, be re-incorporated to new 
phospholipids or degraded enzymatically.
18
 Eicosanoids function as tissue hormones, signalling 
lipids and lipid mediators of inflammation,
19
 messenger molecules that are released from the parent 
cell in response to tissue injury and act at nanomolar concentrations in an autocrine and paracrine 
fashion.
14
 Some of them help to stimulate the action of cells involved in the immune response while 
others help to "turn off" an immune response when it is no longer needed. The ultimate reason for 
the inflammation is to protect the tissue from further damage and to clean it from damaged or dead 
cells and the cell signalling molecules produced by them in order to end the inflammation and heal 
the tissue. 
 
1.4 Newly generated mast cell lipid mediators include Prostaglandin D2 (PGD2) 
 
Prostanoids are a subclass of eicosanoids consisting of prostaglandins, thromboxanes and 
prostacyclins. They are mediators of inflammatory and anaphylactic reactions, and they have 
important roles in maintaining cardiovascular homeostasis and protecting the cardiac tissue against 
oxidative injury in hypoxic conditions.
14
  Prostaglandins are a group of enzymatically derived lipid 
compounds composed of 20 carbon atoms and a 5-carbon ring.
20
 PGD2 is the major eicosanoid 
produced in central nervous system (CNS) and peripheral tissues
21
 and its functions include 
promotion of sleep, thermoregulation, olfactory functions, hormone release, nociception (“pain 
sense”) in the CNS, prevention of platelet aggregation and induction of vasodilation and 
bronchoconstriction.
5
 In peripheral tissues PGD2 is mainly produced by activated mast cells,
13
 but 
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in some extend also by leukocytes, T helper type 2 (Th2) cells and dendritic cells.
21
 Prostaglandins 
E2 and I2 are said to be the pro-inflammatory prostanoids that enhance vasodilation, vascular 
permeability and oedema formation
14
 while PGD2 has both inflammatory and anti-inflammatory 
capacity.
21
 The effect of PGD2 depends on the combination of disease etiology, cell types included 
and the expression profile of eicosanoid receptors in the recipient cells.
21,22
 PGD2 has a short half-
life
5
 and it is readily dehydrated both in vitro and in vivo
5
 or further metabolized to 9α, 11β-PGF2.
11
  
PGD2 can also be transported to the extracellular space by a PG transporter.
11
 
 
1.5 PGD2 biosynthesis 
 
1.5.1 COX-1 and COX-2 produce Prostaglandin PG(H)2 from arachidonic acid 
 
Several enzymes use arachidonic acid as their substrate for eicosanoid biosynthesis and free 
arachidonic acid has three main metabolic pathways to form eicosanoids.
14
 These pathways include 
enzymes called cyclooxygenase (COX), lipoxygenases (LOX) and cytochrome P450 enzymes.
14
 
The COX –pathway (Fig. 2) and the concomitant production of prostaglandins is the focus of this 
study while the two other pathways are not discussed. COXs are known to metabolize arachidonic 
acid released by phospholipase A2 to prostaglandin PG(H)2. 
21-23
  COXs are bifunctional enzymes 
that have both bis-dioxygenase and peroxidase nature
14
 and they are the rate limiting enzymes in the 
production of PGD2 from arachidonic acid.
20
 COXs catalyze cyclooxygenase (bis-oxygenase) 
reactions in which arachidonic acid and two molecular oxygens combine to form PGG2, the 
physiologically important substrate of cyclooxygenase and hydroperoxidase reaction where PGG2 is 
reduced to PGH2 with the help of two electrons.
24
  
 
There are two main isoforms of COXs: COX-1 and COX-2.
14
 Although both isoforms catalyze the 
same reaction and their gross kinetic properties (Km, Vmax) are similar, there are differences in the 
structure of the active site, sequence of the lipid binding domain and biology of the two isoforms.
24
 
In many cell types, COX-1 is localized to ER and nuclear membrane, while the COX-2 isoforms is 
even more concentrated in the nuclear membrane.
24
 COX-1 is constitutively expressed in most cells 
and it is the source of prostanoids that serve to promote housekeeping functions vital for normal 
physiological activities of cells.
14
 COX-2 is most of the time undetectable but can be rapidly 
induced by inflammatory stimuli such as pro-inflammatory cytokines, hormones and growth 
factors.
14,21
 COX-2 messenger RNA levels are also known to rapidly degrade
20
 after inflammatory 
stimuli.  
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All that said both COX-1 and -2 may contribute to the acute inflammatory response. The type of the 
isoform mainly responsible for the inflammation and the type of eicosanoids produced from the 
arachidonic acid depends first of all on the proteome within the cell and especially on the relative 
amounts of the two isoforms present in the tissue in question as well as on their downstream 
enzymes.
14,21,22
 The synthetic profile can be further altered by means of inducible forms of certain 
synthases that require environmental or exogenous signals such as IL-8 for their activation.
14
  Also 
the physical compartmentalization of the COX-1 and -2 enzymes with other enzymes next in the 
pathway might link the activity of a certain isoform with the synthesis of certain eicosanoids.
14
  
Major proportion of eicosanoids generated by mast cells consist of PGD2 synthesized via COX 
pathway and leukotriene C4 (LTC4) synthesized via 5-lipoxygenase pathway.
14,21
  
 
Figure 2: COX pathway 
leading to the production of 
prostaglandins. The two COX 
enzymes, COX-1 and COX-2, 
metabolize phospholipase A2-
derived arachidonic acid to 
prostaglandin PG(H)2, the 
common precursor for 
eicosanoids and substrate for 
other downstream enzymes. 
(http://www.intechopen.com/boo
ks/an-update-on-
glomerulopathies-etiology-and-
pathogenesis/glomerulonephritis
-and-cellular-regulation-of-
prostaglandin-synthesis 
14.10.2013) 
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1.5.2 PGD synthases catalyze the formation of PGD2 from prostaglandin PG(H)2 
 
1.5.2.1 LPGDS 
 
Two distinct types of the PGD synthase (PGDS) have been identified; the lipocalin-type LPGDS 
and the hematopoietic enzyme HPGDS. Despite the differences in catalytic properties, amino acid 
sequence, gene and tertiary structure, cellular localization and tissue distribution, both enzymes 
isomerize PGH2 (Fig. 2), the product of COX-enzymes and a common precursor for all prostanoids, 
to PGD2 and its anti-inflammatory metabolite 15-deoxy- Δ12-14 PGJ2 (15d-PGJ2) in a specific, 
glutathione-dependent manner.
5,22,25
 Lipocalin-type PGD synthase also known as glutathione-
independent PGDS, β-trace protein, prostaglandin-H2 D-isomerase, the brain type enzyme or 
glutathione (GSH)-independent enzyme is a multifunctional protein,
25
 that belongs to the lipocalin 
protein family that consists of lipophilic ligand carrier proteins and retinoic acid binding proteins.
5
 
LPGDS is localized in the central nervous system and male genital organs of various mammals and 
also in the human heart. In addition to its PGD2-producing activity LPGDS functions as an 
extracellular transporter for small lipophilic molecules like for example haem metabolites, retinoids, 
thyroid hormones, steroids, flavonoids and saturated fatty acids, as an endogenous somnogen or an 
agent that promotes sleep, in allergic responses and in clearing the body quickly from harmful or 
otherwise unwanted lipophilic molecules.
26
 LPGDS binding to haemin, biliverdin and bilirubin 
likely protect these from enzymatic catalysis.
26
 
 
1.5.2.2 HPGDS 
 
The hematopoietic enzyme HPGDS also known as the spleen type enzyme or GSH-requiring 
enzyme is a key enzyme in the production of D and J series of prostanoid. HPGDS has previously 
been identified to be expressed in antigen presenting cells, megakaryocytes, type 2 helper T 
lymphocytes, microglia and dendritic cells of many tissues.
5,20
 HPGDS is localized in the mast cell 
cytosol
21
 and it is approximately of the size of 26 kDa. Hyo et al. 
27
 have found that HPGDS is 
involved in activation and differentiation of mast cells. HPGDS can be up regulated
5
 and induced 
by KIT in immature mouse bone marrow derived mast cells and the induction is further enhanced 
by IL-3, IL-9 and IL-10.
28
 These mast cells also show highly increased PGD2 production when 
cultured with KIT and IL-3, IL-9 or IL-10, sensitized with IgE and activated with αIgE.28 The 
increase is dose-dependent for KIT and the interleukins
28
. IL-9 together with KIT enhances the long 
term viability of mast cells while IL-3 can inhibit the final stages of differentiation and maturation 
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of mast cells.
2
 The regulatory mechanisms and the function of HPGDS in mast cells are still largely 
unknown. 
 
1.6 Lipid droplets 
 
Lipid droplets (Fig. 1) also known as lipid bodies, consist of a neutral lipid core surrounded by a 
monolayer of amphipathic lipids such as phospholipids and unesterified cholesterol and by proteins 
involved in the turnover of lipids as well as formation and trafficking of the lipid droplets.
19,29
 The 
major phospholipids include lyso-phosphatidylcholine, phosphatidylcholine and sphingomyelin.
29
 
The proteins are either embedded in the membrane or associate with it through electrostatic 
interactions.
19
 The lipid monolayer is fluid and allows lateral movement of the associated proteins.
30
 
Depending on the cell type, the core is composed mainly of triglycerides, cholesterol esters, other 
esters and diacylglycerol.
31,32
 The neutral lipids in the core and the phospholipids in the surrounding 
monolayer supply fatty acids for various needs, and these fatty acids need to be replenished rapidly 
after usage by re-esterification or re-acylation reactions. Fatty acids are believed to cycle between 
the core and the surrounding lipid monolayer in order to maintain the homeostasis between 
triglycerides and phospholipids.
12
 Metabolic functions of lipid droplets include anabolic reactions 
such as fatty acid synthesis and activation, biosynthesis of sterols and triglyceride molecules, and 
catabolic reactions such as hydrolysis, mobilization and modification of lipid droplet components.  
 
Lipid droplets are found in almost every cell type and virtually all cell types are capable of 
accumulating and storing neutral lipids in lipid droplets the number of which increases in cells at 
sites of inflammation.
23,29,33
 As with the cell membranes; the composition of lipid droplet 
macromolecules varies depending on the cell type and the metabolic state of the cell.
29
 In 
adipocytes, lipid droplets store metabolic energy in the form of triglycerides, and hydrolysis of 
these triglycerides (TGs), known as lipolysis, provides energy during conditions such as fasting or 
starvation.
34
 Excessive lipolysis can lead into accumulation of toxic lipid intermediates and 
oxidized lipids. This is why the cellular hydrolysis of triglycerides is carefully controlled to meet 
the prevailing needs.
34
 Characterization of lipid droplets in some cell types has shown that they are 
active and important sites for arachidonic acid metabolism,
23,35
 and a source of substrates for the 
eicosanoid biosynthesis.
1,19
 Arachidonic acid-derived products are not stored, but instead are very 
unstable and synthesized de-novo when needed. In leukocytes a major proportion of arachidonic 
acid is found in lipid droplet triglycerides. For most other cell types the function and the 
biochemical content of lipid droplets is less well known
23
 although disturbances in lipid droplet  
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metabolism are known to be involved in some of the most widespread human diseases, such as 
atherosclerosis and diabetes.
31,36
 
 
1.7 Mast cell lipid droplets 
 
According to current scientific articles lipid droplets in mast cells are evidently equivalent to those 
in other types of inflammatory cells.
29
 However the cytoplasmic lipid droplets of mast cells are less 
well studied.
1
 Mast cell lipid droplets can be recognized as electron-dense organelles of different 
sizes and increase in number during the differentiation of mast cells.
29
 They are present in mast cells 
of healthy tissues as well as in mast cells which have been found at sites of inflammation.
23
  The 
accumulation of lipid droplets in mast cells is a process that seems to be different from that of 
adipocytes.
1
 Typically there are less than 10 lipid droplets per mast cell
1
, but immunological 
challenge,
1
 developmental abnormalities or environmental challenges can also lead to a rapid 
increase in the number of cytoplasmic lipid droplets in mast cells.
31
 The developmental 
differentiation of CD34+ progenitor cells into mature mast cells is associated with an increase in 
number and size of their cytoplasmic lipid droplets.
29
 Cytoplasmic lipid droplets are not co-secreted 
with the granules upon mast cell activation, but instead are granule- independent organelles.
29
 
Electron microscopic, auto radiographic studies of mast cells have demonstrated that exogenous 
radiolabeled arachidonic acid is incorporated into lipid droplet triglycerides and that the lipid 
droplet formation itself is also stimulated by unsaturated fatty acids, such as oleic acid and 
arachidonic acid.
29,33 
  
1.8 Mast cell lipid droplets could release arachidonic acid from two different 
sites 
 
Arachidonic acid is known to control cell activation, metabolism, cell migration, proliferation and 
death by the induction of apoptosis.
33
 The availability of free arachidonic acid is a rate-limiting step 
in the generation of mammalian eicosanoids.
37
 In the resting cells arachidonic acid is esterified into 
glycerol and stored in the glycerophospholipids of the cell membrane and other membrane 
structures.  The cellular concentrations of free arachidonic acid are low under physiological 
conditions.
14
 Arachidonic acid can be released from different sub-cellular compartments such as the 
nuclear envelope, the phagosome, ER or lipid droplet membrane.
11,35
 Free arachidonic can also be 
incorporated back to other (phospho)lipids or it can leave the cell by diffusion. Arachidonyl-
coenzyme A (CoA) -synthase acts on free arachidonic acid and Coenzyme A to synthesize an 
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unsaturated fattyacyl-CoA regulating the eicosanoid production. The enzymatic products 
arachidonyl-CoA and HETE-CoA do not accumulate in the cells but are instead re-incorporated into 
(phospho) lipids.
38
 
 
Figure 3: Mast cell arachidonic 
acid release. Both 
phospholipases and triglyceride 
(i.e. triacylglycerol) lipases can 
release arachidonic acid from 
mast cell lipid droplets 
(Dichlberger, A., Kovanen, P.T., 
Schneider, W.J.). 
12
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1.8.1 Phospholipases release arachidonic acid from the phospholipid monolayer 
 
In mast cells PGD2 can be produced through three main steps from two different sites (Fig. 3). Free 
arachidonic acid released by phospholipases is oxidized by cyclooxygenases COX-1 and/or COX-2 
to produce prostaglandins via PGH2; by lipoxygenases to produce hydroperoxyeicosatetraenoic 
acids (HPETEs) and leukotrienes; or by cytochrome P450 epoxygenase and ω-hydroxylase to 
produce epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs), 
respectively. 
12,19
 
 
The action of different phospholipase enzymes, mainly activated cPLA2α14,20,37 also known as 
group IVA PLA2,
33
 release arachidonic acid from the sn-2 position of phospholipids such as 
phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylinositol (PI) in 
membranous structures in response to a variety of immunoinflammatory stimuli.
37
 Depending on 
cell type and stimulation conditions also other phospholipase A2 enzymes may contribute.
37
 A rise 
in intracellular calcium level causes the resting state cPLA2-α to translocate to the vicinity of its 
arachidonic acid containing phospholipid substrates and the downstream enzymes of the 
arachidonic acid cascade
35
 and allows the targeting and binding of cPLA2-α to membrane structures 
through its Ca
2+ 
binding domain.
35,37
 The Ca
2+
 -dependent
37
 activation of cPLA2- α can be initiated 
by receptor mediated agonists, microorganisms, phagocytic particles and non-specific stimuli such 
as cell or tissue damage.
14
  In addition to intracellular calcium flux also specific downstream 
signalling events such as phosphorylation by mitogen activated protein kinases (MAPKs) and ERK 
are needed to functionally activate the enzyme.
11
  Lipid droplet-translocated and activated cPLA2-α 
becomes enzymatically active
35
 and specifically recognizes the sn-2 acyl bond of amphipathic lipids 
in the lipid monolayer and catalytically hydrolyzes the bond releasing fatty acids (arachidonic acid) 
and lysophospholipids,
33
 rapidly increasing the amount of free arachidonic acid. A correlation has 
been found to exist between the expression level of cPLA2α and the amount of PGD2 released.
37
 In 
epithelial cells stimulation with arachidonic acid or oleic acid has been shown to trigger the 
translocation of cPLA2-α as well.35   
 
1.8.2 Arachidonic acid in triglycerides of mast cell lipid droplets 
 
In addition to membrane phospholipids, the human mast cells contain a huge amount of arachidonic 
acid incorporated in triglycerides stored in the cores of their cytoplasmic lipid droplets.
29
 Whereas 
the liberation of arachidonic acid from phospholipids by phospholipase family members is well-
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studied, the hydrolysis of arachidonic acid containing triglycerides for the use of eicosanoid 
biosynthesis is less well understood. It is known that exogenous arachidonic acid can be 
incorporated into mast cell triglycerides, and that such incorporation enhances lipid droplet 
formation in the cells.
29
 Thus, mast cell lipid droplets may serve as a cytoplasmic storage site for 
arachidonic acid.
29
 Putative cytosolic lipases that release arachidonic acid from the triglycerides in 
the lipid droplet core include ATGL (adipose triglyceride lipase) and HSL (hormone sensitive 
lipase). 
 
1.8.2.1 ATGL 
 
Triglyceride lipases are enzymes capable of hydrolyzing ester linkages of triglyceride fatty acids. 
ATGL catalyzes the rate limiting reaction of triglyceride hydrolysis,
39
 and initiates the lipolysis 
acting on triglycerides, releasing diacylglycerols and non-esterified free fatty acids (NEFAs), the 
latter of which in case of adipose cells are liberated into the blood circulation to provide energy for 
energy-poor tissues.
39
 There is no report in the scientific literature so far that would state, that ATGL 
releases arachidonic acid from mast cell triglycerides in lipid droplets. ATGL belongs to a human 
patatin-like phospholipase gene family (PNPLAs) containing five members in vertebrates
19
, and it 
is widely expressed in a variety of cells.
34
   In adipocytes ATGL appears to be distributed between 
the cytoplasm and lipid droplets.
19
 Induction of triglyceride hydrolysis requires binding of ATGL to 
the lipid droplet surface and its activation.
34
 
 
1.8.2.2 HSL 
 
The triglyceride lipase activity of ATGL is followed by the action of HSL on diacylglycerols.
19,40
  
HSL is an intracellular neutral lipase that exists as a functional dimer composed of homologous 
subunits. The dimer has greater enzymatic activity compared with monomeric HSL.
41
 HSL is a 
multifunctional enzyme that can act on triglycerides,
40
 diacylglycerols, monoacylglycerols, 
cholesterylesters and other water-soluble substrates. However, it shows preference for 
diacylglycerols.
41
 Although HSL functions in hydrolysis of fatty acids in di- and triglycerides of 
lipid droplets, the enzyme preferentially releases polyunsaturated fatty acids, and has the capacity to 
hydrolyze diacylglycerols much faster than triglycerides (triacylglycerols).
40
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1.8.3 PAT proteins regulate the activity of HSL and ATGL 
 
Lipolysis and lipid droplet metabolism is regulated by the composition of the lipid droplet-
associated proteins on the lipid droplet surface. The most prominent proteins are PAT proteins.
29,34
 
The PAT protein family includes PLIN 1 also known as perilipin 1, perilipin 2 (PLIN 2) also known 
as adipophilin, perilipin 3 (PLIN 3) also known as TIP47, perilipin 4 (PLIN 4) also known as 
adipocyte Protein S3-12 and perilipin 5 (PLIN 5) also known MLDP (OXPAT/PAT-1)
19
 and lipid 
storage droplet protein 5 also known as LSDP5. Regulation of PAT expression and hence also the 
activity of lipolytic enzymes is tissue specific.
34
 Mammalian lipid droplets contain one or more of 
these six PAT proteins,
19
 and PAT genes are transcribed also in human mast cells.
29
 They regulate 
the basal and induced lipolysis of stored neutral lipids
19
 by controlling the access of lipases to the 
lipid droplet core and the exposure of the triglycerides of lipid droplets to enzymatic actions of 
lipases
40
 by means of lateral movement within the lipid droplet membrane
30
 and on the other hand 
by serving as structural components that stabilize lipid droplets.
30
  PAT proteins are also thought to 
serve as scaffolds via which recruitment and reorganization of other proteins to the lipid droplet 
surface occurs.
29
 In non-activated cells (Fig. 4) perilipin coats the lipid droplet surface and interacts 
with CGI-58, a highly conserved protein co-activating factor of ATGL,
29
 while HSL is dispersed in 
the cytoplasm.
40
 
 
Upon lipolytic stimulation, phosphorylation of both perilipin and HSL by cAMP activated Protein 
kinase A (PKA) is required. PKA is an enzyme known to participate in the regulation of glycogen, 
sugar, and lipid metabolism in a wide variety of cells in a cyclic AMP (cAMP) dependent manner.  
The phosphorylation leads to a stimulated condition where CGI-58 is released from perilipin and 
HSL is recruited into lipid droplet surface.
19,30,39
 Free CGI-58 binds exclusively ATGL
40
 recruiting 
it to the lipid droplet surface via protein-protein interaction and activating its lipolytic functions
34,40
 
and stimulating the triglyceride hydrolysis and concomitant formation of diacylglycerols by 20-fold 
at its best.
19,40
 The phosphorylation of HSL by PKA affects HSL enzyme activity or its access to 
substrates.
30
 Simultaneous phosphorylation of both perilipin and HSL is necessary for complete 
hydrolysis of triglycerides
40,42
 since only phosphorylated HSL can act on diacylglycerols and hence 
continue the lipolysis started by ATGL. Hydrolytic activity of HSL against triglycerol or 
monoacylglycerol is however unaffected by phosphorylation,
41
 which is probably one of the reasons 
for HSL’s preference for diacylglycerols. HSL activity can be inactivated by protein phosphatases.41 
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 PAT proteins likely affect mast cell lipid droplet hydrolysis. Perilipin 2 is expressed in small 
amounts in all mammalian cell types analyzed so far
31
 and highly expressed in the developing and 
mature mast cells, where it locates at the circumferential surface of lipid droplets.
29,31,43
  PLIN2 
shields the triglycerides stored in the lipid core from the activity of cytosolic lipases
19
 by controlling 
the lipolysis catalyzed by Protein kinase A phosphorylated HSL
30
 and by regulating the ATGL 
enzyme activity in a reducing manner
39
. Expression of the PLIN2 gene is itself regulated by the 
prostaglandins, PGI2 and PGJ2 from the COX-2 pathway.
31
 
 
 
Figure 4: The regulation of HSL and ATGL activity by the PAT protein Perilipin. Phosphorylation of 
Perilipin and HSL is known to lead to activation of ATGL by CGI-58.
40
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2 Aim of the work 
 
Lipid droplets have been extensively studied in adipocytes and in macrophage foam cells, where the 
organelles are easy to recognize and visualize, but lipid droplet (LD) biology in mast cells has 
gained less interest.  Although lipid droplets (LDs) have been identified as a site for the conversion 
of arachidonic acid released from phospholipids by phospholipases into eicosanoids, the mechanism 
by which arachidonic acid in triglycerides is formed and mobilized has remained mainly 
undefined.
29
 Much more is known about the eicosanoid metabolism of arachidonic acid released 
from phospholipids by action of Phospholipase A2 (cPLA2). The aim of the study was the 
elucidation of molecular mechanisms involved in the generation of eicosanoids in human mast cells 
with particular emphasis on triglyceride-rich lipid droplets as a source and/or site of lipid mediator 
genesis. 
 
We were interested in finding out which are the enzymes involved in arachidonic acid liberation 
from triglycerides in lipid droplet core and whether the arachidonic acid from triglycerides in lipid 
droplets is used for the biosynthesis of eicosanoids, especially the PGD2.  If the lipid-body core 
triglycerides are the immediate source of arachidonic acid there should be a lipase that is able to 
respond to cell activation and to mobilize arachidonic acid from triglycerides. We hypothesized that 
ATGL and/or HSL are putative enzymes in the liberation of arachidonic acid from the lipid droplet 
triglycerides in mast cells. In addition we were also interested if mast cell lipid droplets are the 
actual cellular compartments of PGD2 synthesis. Of all the related enzymes, we were especially 
interested in the role and presence of HPGDS in lipid droplets.  
 23 
 
3 Materials and methods 
 
3.1 Cell culture 
 
Because mast cells do not circulate in peripheral blood and are difficult to obtain and culture from 
tissue, mature human mast cells were generated according to a well-defined protocol established in 
our laboratory.
16
 For this purpose, CD34
+
 progenitors were obtained from fresh buffy coats prepared 
from peripheral blood of healthy blood donors (Finnish Red Cross Blood Transfusion Service, 
Helsinki, Finland).   The blood sample was transferred into a cell culture bottle containing 
Ca
2+
/Mg
2+
 -free PBS and layered on top of Ficoll-Paque (1.77g/l) (Amersham Biosciences 17-1440-
03; 500ml). During centrifugation  at 800 x g for 30 minutes at room temperature (RT) the Ficoll-
Paque fractionated the blood into layers of plasma, buffy coat (the interface containing mononuclear 
cells), and red blood cells. The isolation of CD34
+
 cells was carried out with indirect CD34 
MicroBead Kit (#130-046-701; MACS®). The buffy coats were  washed twice with Ca2+/Mg2+ –
free PBS  and centrifuged at 800 x g for 10 minutes at room temperature and then twice at 200 x g 
for 10 minutes.  The cells were then re-suspended into Dulbecco's Modified Eagle Medium 
(DMEM, Life Technologies) containing Penicillin Streptomycin mixture.  Cell number and viability 
were determined using a NucleoCounter® NC-200™.  The cell suspension was centrifuged at 300 x 
g for 10 minutes and re-suspended in 400 µl of BIT per 10
8
 cells. One hundred microliters of FcR 
blocking reagent were added and after mixing, the cells were incubated for 15 minutes with 100 µl 
of CD34-Hapten-antibody per 10
8
 total cells. The cells were then washed with 5-10 ml of BIT per 
10
8
 cells, centrifuged at 300 x g for 10 minutes and re-suspended in 400 µl of the buffer. After this, 
100 µl of Anti-Hapten MicroBeads per 10
8
 cells were added and the mixture was incubated for 15 
minutes.  Final washing was done by adding 10 ml of BIT per 10
8
 cells and centrifuging at 300 x g 
for 5 minutes. The cells (up to 10
8
) were then re-suspended in 3 ml of BIT, and loaded onto a 
MACS ® column which was placed in a magnetic field. The eluates were collected by 
centrifugation (300 x g´s for 5 min), re-suspended in a serum free BIT-medium containing KITL 
(100 ng/mL) and IL-3, and cultured on 6-well plates. Culturing proceeded under serum-free 
conditions in Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco® by Life Technologies) 
supplemented with BIT 9500 serum substitute (Stem cell Technologies), L-glutamine (2 mM), 2-
mercaptoethanol (0.1 mM), penicillin (100 U/ml), and streptomycin (100 µg/ml), human 
recombinant KITL (100 ng/mL) and different human recombinant cytokines according to a method 
presented by Lappalainen et al.
16
 The weekly incubation schedule can be found as an attachment at 
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the end of this thesis (Attachment 1). The cells were cultured in a humified incubator at + 37 °
C
. 
Cell number and viability were determined from the week two onwards using the NucleoCounter® 
NC-200™. For optimal cell growth, the cell density was maintained at 5x105cells/ml. The cells 
chosen for each experiment were maintained i.e.  1ml of BIT-medium was added per 500 00 of re-
suspended cells the previous day, and were most often on 6
th
 or 7
th
 week of culture. 
 
3.2 Oil-Red-O staining   
 
Cytospins were prepared in duplicates, 25 000 cells/slide (Cytospin2 SHANDON Instruments).  
Then slides were fixed in 4% neutral-buffered formalin for 30 seconds, rinsed with running tape 
water for 10 minutes, incubated for 5 minutes in 100% Propylene glycol and stained for 30 minutes 
with Oil-Red-O (2.8 g Oil-Red-O, SIGMA), and 400 ml propylene glycol.  Then the slides were 
incubated for 1 minute in 85% Propylene Glycol, rinsed with H2Odd, and stained for 1min in 
Mayer´s Hematoxylin. Finally, slides were rinsed with tape water and H2Odd before mounting 
them with Fluorescent Mounting Medium (Dako).  Images were captured with Nikon ECLIPSE 
E600, magnification 40x.  
 
3.3 Basic molecular biological methods 
 
3.3.1 RNA isolation and cDNA synthesis 
 
Total RNA was isolated from the human mast cells using the NucleoSpin®RNA II kit (Macherey 
Nagel). Isolation of RNA was performed according to the manufactures instructions. All 
centrifugation steps were carried out at room temperature for 1 min at 11,000 x g. Briefly, mast cells 
were lysed with 350 µl of Buffer RA1 containing 3.5 µl of β-mercaptoethanol, and RNA was 
precipitated by adding 350 µl of 70% ethanol. RNA precipitates were loaded on the columns 
provided.  The silica membrane was desalted with 350 µl of MDB (Membrane Desalting Buffer)  
and on-column DNA digestion was performed for 15 minutes at room temperature using 95 µl of  
rDNase reaction mixture (10 µl of  reconstituted rDNase and 90 µl of  Reaction Buffer for rDNase). 
rDNase was inactivated with 200 µl of  Buffer RA2. RNA was washed twice with Buffer RA3. 
Finally, RNA was eluted with 30 µl of RNase-free H2Odd. RNA concentration was measured with a 
NanoDrop ND-1000 Spectrophotometer. 
 
cDNA was generated from 500 ng of total RNA by First-strand synthesis using random hexamers 
and M-MLV reverse transcriptase -enzyme according to the manufacturer’s instructions (Promega). 
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Briefly, 3 μl of reaction Mix 1, containing 1 µl of 10mM dNTP mix, 1 µl of Random primers 
diluted to 200 ng/µl and 1 µl RNase-free water, was added to each sample tube containing 500 ng 
RNA in a total volume of 11 l. Samples were incubated at 65° for 5 minutes in a Eppendorf 
Mastercycler gradient, program JLRT1, and then chilled on ice for 2 minutes. Then, 6 µl of reaction 
Mix 2 containing,  0.75 µl of RNase-free water, 4 µl  of 5X First Strand Buffer, 0.5 µl RNase 
Inhibitor (40U/ µl), and 0.75 µl of M-MLV RT enzyme (200U/ µl) was added to each RNA/primer 
mixture. First strand cDNA synthesis was continued according to the following program: 8 minutes 
at 25° to ensure primer annealing, 55 minutes at 48° for first strand synthesis and 10 minutes at 95° 
to terminate the reaction. The cDNA samples were stored at -20°. 
 
3.3.2 Quantitative PCR (qPCR) 
 
For qPCR, cDNA was amplified in duplicates using either TaqMan Universal PCR Master Mix 
(Applied Biosystems) or Power SYBR Green PCR Master Mix (Applied Biosystems) with gene-
specific oligonucleotides and fluorogenic TaqMan probes on an ABI PRISM 7500 sequence 
detector system (Applied Biosystems). Specific oligonucleotides and probes were designed for 
ATGL, HSL, CGI-58, COX-1, COX-2, HPGDS and GAPDH (Table 1). To compare the expression 
of the genes chosen, relative quantification was used and data were normalized to the expression of 
GAPDH. The normalization of qPCR results was done using the Delta-delta CT calculation method, 
which gives the ratio of the target gene in ones treated sample relative to ones untreated sample by 
taking 2
ΔΔCT
, assuming that the amplification efficiency in each PCR cycle for both the reference 
control gene and the target gene have been 100%.
44
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Table 1: Primers and probes used in quantitative real-time RT-PCR 
Sequence 
ATGL -F* 5' - CAGACGGCGAGAATGTCATT - 3' 
ATGL -R# 5' - AAATGCCACCATCCACGTAG- 3', 
HSL-F 5' - GAGTGCTAGGCACATAGTCCCCTCC- 3'  
HSL-R 5' - GCGGGGTTATAGGCCTCTGGTG- 3' 
hsCGI58_F2 5' - AGCCTTGGGGTTTCCCTGAACG- 3' 
hsCGI58_R2 5' -AATCAGGCCTTAAACGCTGCACT- 3' 
COX-1 -F 5' - CACAGTGCGCTCCAACCTTA- 3'   
COX-1 -R 5' - TGGAGAAAGACTCCCAGCTGA- 3' 
COX-1 probe 5' - CTTATCCCCAGTCCCCCCACCTACAACTC- 3' 
COX-2 -F 5' - GGCGCAGTTTACGCTGTCTAG- 3'  
COX-2 -R 5' -CGAGGGCCAGCTTTCAC- 3' 
COX-2 probe information unavailable
HPGDS-F 5' -ATGCGCCTCATCTTATGCAAG- 3'  
HPGDS-R 5' -GGTTGTCTAACAGGTCAGGCT- 3'
GAPDH-F 5' -GTCAACGGATTTGGTCGTATTGG- 3' 
GAPDH-R 5' -GGCAACAATATCCACTTTACCAGAGT- 3'
GAPDH probe 5' - TGGTCACCAGGGCTGCTT- 3'
* forwar primer
# reverse primer
Primer or probe
 
 
3.4 Basic molecular biochemical methods 
 
3.4.1.1 Preparation of protein lysates 
 
For the preparation of total cell lysates, mast cells were washed twice with PBS, lysed in ice-cold 
cell lysis buffer (25 mM Tris/HCl pH 7.4, 150mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol) 
containing complete protease inhibitor cocktail (Roche). Protein concentrations were determined by 
using BCA protein kit from Pierce (Pierce ® BCA Protein Assay Kit, Thermo Scientific Prod # 
23225, Lot # MA152117). 
 
3.4.1.2 Western blot analysis 
 
Proteins were separated by SDS-PAGE (10 % gels; 1,5 mm) under reducing condition, and then 
transferred onto a nitrocellulose membrane by semi-dry blotting for 1h at 200 mAmp using 1x 
transfer buffer (10x Transfer buffer for Wet Blot or Semi-Dry Blot 250mM Tris, 1.92M Glycine, in 
1:10 dilution) (Hybond-C Extra; Amersham Biosciences). Non-specific binding sites were blocked 
with 5% non-fat dry milk in 1x TBS-T buffer (150 mM NaCl, 10 mM Tris, 0.1% Tween-20, pH 8) 
for 1 hour at room temperature. Immunodetection was performed using mouse anti-human HPGDS 
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(0.1 µg/ml; MAB6487; R&D Systems) followed by incubation, according to the primary antibody, 
with horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (1:2000 dilution; 0447; DAKO). 
The GAPDH antibody (Monoclonal α-GAPDH mouse IgM isotype, cat No. G8795 SIGMA-
ALDRICH) was used in 1:2000 dilutions followed by incubation and immunodetection with HRP-
conjugated goat α-mouse IgG in 1: 25000 dilutions (DAKO). The signals were detected using an 
enhanced chemiluminescence method (PIERCE). 
 
3.5 siRNA transfection 
 
ATGL and HSL were specifically knocked down by small interfering RNAs (siRNAs) purchased 
from QIAGEN (for product details see table 2). Mature human mast cells were freshly maintained 
24 h prior transfection.  For siRNA transfection mast cells were collected by centrifugation at 300 x 
g for 5 minutes, and cell density was adjusted to 250 000 cells/100 µl pre-conditioned medium. The 
remaining pre-conditioned medium was collected and stored at +4
o 
C. The cells were seeded on 24-
well plates at a density of 2.5 x 10
5 
cells/100 µl/well. RNA:lipid complexes were generated as 
follows: the siRNAs (molar ratio 1:1:1:1; total of 100nM) were mixed with  pre-conditioned 
medium and HiPerfect transfection reagent.  The siRNA:lipid complexes were allowed to form 
during a 10-minute incubation at room temperature. siRNAs for human ATGL (GeneSolution 
siRNA, cat.No. SI03019310; SI03019611; SI05654397; SI05654404, QIAGEN), and human HSL 
(GeneSolution siRNA, cat. No., SI00470834; SI04159904 ; SI04208659 ; SI04280346 , QIAGEN) 
are indicated in table 2.  Cells were transfected with siRNAs or 100nM Allstar negative control 
siRNA AF488. Twenty hours after transfection, the cells were subjected to immunological 
activation as described below. 
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Table 2: siRNAs used in siRNA transfection of human mast cells 
siRNA Product name Coding sequence
ATGL Hs_PNPLA2_5 CAAGTTCATTGAGGTATCTAA
ATGL Hs_PNPLA2_6 GACGGCGAGAATGTCATTATA
ATGL Hs_LOC100507839_2 AAGTTCATTGAGGTATCTAAA
ATGL Hs_LOC100507839_3 CAACACCAGCATCCAGTTCAA
HSL Hs_LIPE_3 CAGCAGCCTGATAAAGTCCAA
HSL Hs_LIPE_5 CCGCTAGAGCCTGGGCCAGAA
HSL Hs_LIPE_6 CCCTCCGATGTCAACTTCTTA
HSL Hs_LIPE_7 CAGGAACTATCCATACAGCGA
 
 
3.6 Mast cell activation 
 
For immunological activation via IgE receptor cross-linking, mast cells were first sensitized for 3 
hours with human IgE (1µg/ml, DiaTec), and then activated by incubation in the presence of 
polyclonal rabbit anti-human IgE (1µg/ml, Millipore) for different periods of time. Mast cells 
incubated for 3 hours with 1µg/ml IgE alone were used as non-activated controls. 
 
3.7 PGD2 MOX EIA 
 
The quantities of PGD2 released from mast cells into the culture medium were analyzed by using 
commercial enzyme immunoassays (Prostaglandin D2-MOX EIA Kit, Cayman Chemicals) 
according to the manufacturer’s protocols. Briefly, the assay is based on the conversion of PGD2 to 
a more stable MOX-derivative by methoxylamine hydrochloride treatment. Preparation of the 
methoximated PGD2 standards was performed according to the assay protocol. Standards, controls 
and samples were prepared in duplicates according to the protocol in the kit. NSB controls were 
prepared by mixing 105 µl of BIT, EIA buffer and Tracer each and B0 control by mixing 52.5 µl of 
BIT and EIA buffer with 105 µl of Tracer and Antiserum. Standards and samples were prepared by 
mixing 105 µl of sample or standard with equivalent amounts of Tracer and Antiserum. Blank and 
TA control wells were kept empty; the well plate was sealed and then incubated over night at 4ºC.  
The ELISA development was done by washing all wells with 5 times 200 µl EIA Wash-buffer after 
which 200 µl Ellmann’s reagent was added to each well. The TA wells received 5 µl of Tracer as 
well. The plate was sealed and incubated 1 h at room temperature after which the absorbance at 450 
nm, Scale: 0.000A-2.000A: Absorbance Scale (for photometry) was read with PerkinElmer 
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precisely 1420 Multilabel counter VICTOR 
3
™ and with Wallac 1420 Manager Software. In this 
reading, the more intense the yellow signal is, the less free PGD2 -MOX is present. 
 
3.8 Preparation of FA:BSA complexes 
 
Fatty acid:BSA complexes were prepared as described by Dichlberger et al.
29
 Briefly, stock 
solutions of a fatty acid sodium salt arachidonate or oleate (Sigma, A8798) were combined with a 
stock solution of fatty acid-free BSA (Sigma, A6003) at a molar ratio of 6:1 (fatty acid:BSA) under 
nitrogen at 37°C for 15 min. All stock solutions were prepared in LDL buffer (pH 7.4; 150mM 
NaCl; 0,24mM EDTA). Measurement of fatty acid concentration was carried out using the NEFA 
analysis kit from WAKO. Fatty acid: BSA complexes were used for induction of lipid droplet 
formation in human mast cells. 
 
3.9 Immunofluorescence stainings 
 
Mast cell lipid droplets were induced by exogenous treatment with oleic acid or arachidonic acid 
complexed to BSA (250 µM final fatty acid concentration) for 18 hours. The following day the 
induced cells were activated as mentioned before. The cytospins were prepared in duplicates and 
cells fixed with 4% PFA 0.025% GA in Ca
2+
/Mg
2+
 –free PBS for 20 min in room temperature. The 
slides were then washed four times 5 minutes with PBS on a shaker. Non-specific binding sites 
were blocked with 3% goat serum 0.1% Saponin (Fluka, Lot # 1370302) in PBS (pH 7.4) 
containing 0.2M glycine (SIGMA, product code 101175631 50046-1KG, Lot# BCBG8981V). 
Primary and secondary antibodies were both diluted in 3% goat serum 0.1% saponin in PBS. The 
primary ATGL antibody (Cell Signalling TECNOLOGY, # 2138) was used in 1:100 dilutions and 
the primary HPGDS Antibody (R&D SYSTEMS, HPGDS ANTIBODY Monoclonal Mouse IgG1 
Clone#735301 Cat. No. MAB6487, Lot# CFWO0111081) in 1:200 dilutions. Mouse IgG1 Negative 
/Isotype control (AbD Serotec, MCA928, 0.1mg/ml) was used as negative control. ALEXA 594 
goat α-rabbit IgG (Invitrogen™ Life Technologies, Molecular Probes® A11080, Lot# 459560; 
dilution 1:500) or Alexa Fluor® 594 Goat Anti-Mouse IgG (H+L) (Invitrogen™ Life Technologies) 
were used as the secondary antibody. The primary antibodies were incubated overnight at +4°C and 
the secondary antibodies for one hour at room temperature. Finally, the slides were washed 3 times 
with Ca
2+
/Mg –free PBS for 5 minutes, and counterstained with DAPI.  The lipid droplet content 
was assessed by adding BODIPY fluorescent dye (10 μg /ml) simultaneously with the secondary 
antibody. The slides were mounted using Fluorescent Mounting Medium from Dako and stored 
 30 
 
protected from light. Images were captured with Nikon ECLIPSE E600 (original magnification, 
40x). 
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4 Results 
 
For the generation of mature and functional human mast cells, CD34
+
 peripheral blood progenitors 
were isolated from different human donors and differentiated into mature mast cells under serum-
free conditions for up to 6 to 8 weeks. The presence of cytoplasmic lipid droplets was visualized by 
Oil Red O staining (Fig. 5). The results confirmed the earlier reported observation made in our 
laboratory that not just mature mast cells isolated from human lungs
23
 but also the in vitro-
generated human mast cells derived from peripheral blood progenitor cells contain lipid droplets 
(LDs) in their cytosol.
29
 Already at week 5 of culture, almost all mast cells stained positively for 
lipid droplets; however, in contrast to the lung mast cells,
23
 the lipid droplets were located not 
mainly around the nucleus, but were evenly distributed in the cytoplasm (Fig. 5). The lipid droplets 
were of different sizes, a finding we previously made while studying cultured mast cells under 
culture conditions identical to those described here
29
.   
 
 
Figure 5: Identification of human mast cell lipid droplets with light microscopy on their 5
th
 week of 
culture. CD34
+
 peripheral blood progenitors were isolated from different donors and cultured under serum-
free conditions to generate mature mast cells as described in Materials and methods. The cells were stained 
with Oil Red O and Hematoxylin in week 5 of culture. Mast cells from a single donor are shown at 
magnification 40x. 
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As we were interested in the release of arachidonic acid from lipid droplet triglycerides for the 
purpose of prostaglandin D2 (PGD2) generation upon mast cell activation, we first analyzed the 
gene expression of certain enzymes involved in this process. The biosynthesis of PGD2 is well-
known to proceed via the COX pathway.
21-23
 Cyclooxygenase 1 (COX-1) and cyclooxygenase 2 
(COX-2) catalyze the enzymatic reaction from arachidonic acid to prostaglandin PG(H)2, a common 
precursor for  prostaglandins,
14,21-23
 which is further metabolized by HPGDS to generate PGD2
22
.  
Potent candidates for enzymes releasing arachidonic acid from triglycerides are ATGL and HSL. 
qPCR analysis was used to measure  transcript levels of ATGL, CGI-58, HSL, COX-1, COX-2 and 
HPGDS at different time points after IgE-mediated mast cell activation.  For this purpose mast cell 
RNA was purified using the NucleoSpin®RNA II kit, the RNA was reverse transcribed into cDNA, 
and the cDNA was amplified using qPCR and GAPDH as reference gene for data normalization.  
 
The transcript levels of ATGL did not change at 0.5 and 1 h post-activation, but showed an up-
regulation 2 h after cellular activation (Fig. 6a). CGI-58, the co-activating factor of ATGL, showed 
a slight down regulation of mRNA levels upon mast cell activation, but displayed similar levels at 2 
h post-activation as observed in resting cells (Fig. 6b). HSL transcript levels clearly dropped upon 
mast cell activation and stayed at a lower level compared to resting cells (Fig. 6c) Moreover, we 
analyzed the gene expression of COX-1, COX-2, and HPGDS, which are involved in the generation 
of PGD2. As demonstrated in figures 6d and 6f, neither COX-1 nor HPGDS showed any significant 
changes in mRNA levels upon mast cell activation. In contrast, COX-2 mRNA levels increased 
dramatically by about 40 fold at 1 h post-activation and declined to resting levels at 2 h after mast 
cell activation (Fig. 6e). Since LPGDS does not play any major role in mast cells, analysis of this 
type of Prostaglandin D synthase was not included in this study. 
 33 
 
 
 
Figure 6 a-c: Expression of ATGL, CGI-58 and HSL in sensitized and activated human mast cells. 
Mature human mast cells were activated as described in Material and Methods. The expression levels of 
ATGL, CGI-58 and HSL were determined using qPCR. For data normalization, GAPDH was used as 
endogenous control. Data with cells derived from one representative donor is shown 
 
IgE/anti-IgE            -/-           +/-           +/+          +/+          +/+ 
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Figure 6 d-f: Expression of COX-1, COX-2 and HPGDS in sensitized and activated human mast cells. 
Mature human mast cells were activated as described in Material and Methods. The expression levels of 
COX-1, COX-2 and HPGDS were determined using qPCR with GAPDH as endogenous control. Data with 
cells derived from one representative donor is shown 
 
IgE/anti-IgE            -/-           +/-           +/+          +/+          +/+ 
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Next, we analyzed the amount of PGD2 released from activated mast cells. The amount of PGD2 
released from activated mast cells into the culture medium was measured by a specific ELISA- 
protocol, as described in Materials and Methods. The increase of PGD2 was immediate and most 
prominent after one hour of activation, and slowly decreased to basal levels at 48 h post-activation 
(Fig. 7). 
 
 
 
Figure: 7: PGD2 release from activated human mast cells. Mast cells were immunologically (IgE) 
activated as described in Materials and Methods. PGD2 concentrations (pg/ml) were measured at the 
indicated time points after mast cell activation with a PGD2 mox immunoassay. Data of one representative 
donor is shown.  
 
In order to study whether silencing the gene expression of ATGL and/or HSL would affect the 
quantity of PGD2 released by activated mast cells, siRNA transfections were performed. The siRNA 
method used interferes with the transcription-translation -step silencing the messenger RNA 
(mRNA) levels of the gene in question. Since mast cell activation is known to lead into an increase 
in the amount of PGD2 released, we wanted to test the effect of ATGL- and HSL-knockdowns on an 
early phase (30 to 120 minutes after activation) of PGD2 release. The quantities of PGD2 released 
from ATGL-silenced cells were not different from those in the siRNA control-treated cells (Fig. 8). 
In contrast, knockdown of HSL showed a clear reduction in PGD2 release compared to control cells 
(Fig. 8). Although no effect was observed regarding the quantity of PGD2 released by ATGL-
silenced cells, the knockdown efficiency of ATGL was successful, the ATGL mRNA levels being 
reduced by about 85% compared to control cells as demonstrated by qPCR (Fig. 9). The ATGL co-
activator CGI-58 is known to enhance the activity of ATGL, and knocking down either ATGL or 
HSL had no effect on the expression of CGI-58 (Fig. 10). Silencing of ATGL or HSL had no 
significant effect on each other’s mRNA expression levels (Fig. 9 and Fig. 11).   
IgE/anti-IgE            -/-      +/-     +/+     +/+     +/+    +/+     +/+    +/+     +/+ 
Time (h) 
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Figure 8: Early phase PGD2 release from activated human mast cells after ATGL and HSL siRNA 
knockdowns. Mast cells were activated and the siRNA transfection was performed as described in Materials 
and Methods. PGD2 concentrations (pg/ml) were measured at the indicated time points after mast cell 
activation with a PGD2 mox immunoassay. Data of one representative donor is shown.  
 
 
 
Figure 9: The effect of ATGL and HSL knockdowns by siRNAs for investigating the effect on ATGL 
expression in activated mast cells. Human mast cells were transfected with siRNAs targeting ATGL 
(100nM) or HSL (100nM) for 20 h at 37°C. Control siRNA-transfected cells were used as controls. ATGL and 
HSL mRNA levels were analyzed by qPCR. For data normalization, GAPDH was used as endogenous 
control. Transcript levels are shown as fold changes, and represent data obtained with cells derived from a 
single donor. 
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Figure 10: The effect of ATGL and HSL knockdowns by siRNAs for investigating the effect on CGI-58 
expression in activated mast cells. Human mast cells were transfected with siRNAs targeting ATGL 
(100nM) or HSL (100nM) for 20 h at 37°C. Control siRNA-transfected cells were used as controls. ATGL and 
HSL mRNA levels were analyzed by qPCR. For data normalization, GAPDH was used as endogenous 
control. Transcript levels are shown as fold changes, and represent data obtained with cells derived from a 
single donor. 
 
 
 
Figure 11: The effect of ATGL and HSL knockdowns by siRNAs for investigating the effect on HSL 
expression in activated mast cells. Human mast cells were transfected with siRNAs targeting ATGL 
(100nM) or HSL (100nM) for 20 h at 37°C. Control siRNA-transfected cells were used as controls. ATGL and 
HSL mRNA levels were analyzed by qPCR. For data normalization, GAPDH was used as endogenous 
control. Transcript levels are shown as fold changes, and represent data obtained with cells derived from a 
single donor. 
 
The amount of PGD2 released during the early phase was further tested with an ATGL-HSL –double 
knockdown experiment (Fig. 12). When both ATGL and HSL were knocked down, the quantity of 
PGD2 released did not show any significant reduction compared to siRNA control-treated cells.  
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Figure 12: The effect of ATGL and HSL double knockdown on early phase of PGD2 release. Mast cells 
were activated and the siRNA transfection was performed as described in Materials and Methods. PGD2 
concentrations (pg/ml) were measured with a PGD2 mox immunoassay at the indicated time points after 
mast cell sensitizing and activation. Data of one representative donor is shown.  
 
Since no effects on the release of PGD2 were observed in ATGL single-silenced or ATGL-HSL –
double-silenced mast cells during the early mediator release, we analyzed the immediate (5 min and 
15 min) response of mediator release upon mast cell activation. As shown in Fig. 13, the release of 
PGD2 was reduced in HSL-silenced mast cells and even more pronounced in ATGL single-silenced 
cells at 5 and 15 minutes after mast cell activation compared to control cells.  By far the strongest 
reduction in the acute PGD2 release was seen with the ATGL+HSL –double knockdown and the 
double knockdown of ATGL and HSL reduced the quantity of PGD2 released more than either of 
the two alone. Taken together, the quantity of PGD2 released from mast cells under silencing 
conditions was higher after 15 than 5 minutes of activation. Meaning the silencing was stronger 
after 5 minutes than after 15 minutes. 
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Figure 13: The effect HSL, ATGL and HSL-ATGL -double knockdown on acute PGD2 release from 
activated mast cells. Mast cells were activated and the siRNA transfection was performed as described in 
Materials and Methods. PGD2 concentrations (pg/ml) were measured at the indicated time points after mast 
cell activation with a PGD2 mox immunoassay. Data with cells derived from one representative donor is 
shown.  
 
In ATGL-silenced and ATGL+HSL-silenced cells, the knockdown efficiency of ATGL was 
successful and ATGL mRNA levels were somewhat reduced compared to control cells as 
demonstrated by qPCR (Fig. 14). HSL knockdown had a minimal, but non-significant up-regulating 
effect on ATGL expression (Fig. 14). Moreover, HSL, ATGL and HSL+ATGL knockdowns had 
minimal non-significant up-regulating effects on HSL expression (Fig. 15). All the qPCR data was 
normalized to GAPDH. 
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Figure 14: The effect of ATGL+HSL -double knockdown by siRNAs for investigating the effect on 
ATGL expression in activated mast cells. Human mast cells were transfected with siRNAs targeting ATGL 
(100nM), HSL (100nM) or ATGL+HSL for 20 h at 37°C. Control siRNA-transfected cells were used as 
controls. ATGL and HSL mRNA levels were analyzed by qPCR. For data normalization, GAPDH was used as 
endogenous control. Transcript levels are shown as fold changes and represent data obtained with cells 
derived from a single donor. 
 
 
 
Figure 15: The effect of ATGL+HSL -double knockdown by siRNAs for investigating the effect on HSL 
expression in activated mast cells at their 11
th
 week of culture. Human mast cells were transfected with 
siRNAs targeting ATGL (100nM), HSL (100nM) or ATGL+HSL for 20 h at 37°C. Control siRNA-transfected 
cells were used as controls. ATGL and HSL mRNA levels were analyzed by qPCR. For data normalization, 
GAPDH was used as endogenous control. Transcript levels are shown as fold changes and represent data 
obtained with cells derived from a single donor. 
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In order to obtain information about the intracellular localization of the enzymes of interest, 
immunofluorescence microscopy was used to assess the localization and endogenous expression 
of ATGL in human mast cells. Staining with the ATGL antibody revealed that  ATGL was widely 
dispersed  in the mast cells (Fig.16a).The size of cytosolic lipid droplets was enhanced by 
exogenous fatty acid treatment, but only a few lipid droplets were present (Fig. 16 b) and they 
stained green with BODIPY 493/503 (Fig. 16 c).   
 
 
Figure 16: Intracellular localization of human mast cell ATGL. For the analysis of intracellular 
localization of ATGL, immunofluorescence staining of ATGL in non-activated mast cells on 13th week of 
culture was performed. The cells were induced with 250 mmol of oleic acid for 18 to 20 hours to increase 
their lipid droplet (LD) production. The primary ATGL antibody was probed with Alexa Fluor® 594-
conjugated goat α-rabbit IgG (red). The cells were stained for lipid droplets (LD) with DOBIPY 493/503 
(green), and nuclei were counterstained with DAPI (blue). Merged image is shown in the right-hand 
panel. Data with cells derived from one representative donor is shown. 
 
Moreover, mast cells were also stained for the cellular distribution of HPGDS under resting and 
activated conditions. In the resting Ctrl (Fig. 17a, b, c) and IgE control cells (Fig. 17d, e, f) the 
specific staining for HPGDS was primarily visible in the nuclear and cytosolic area (Fig17a, d). 
Lipid droplets were clearly visible as homogenously stained round-shaped entities (Fig. 17b, c) 
staining positive with BODIPY493/503. The same observation was made in mast cells 15 min 
after IgE-mediated activation (Fig.17g, i). Both, the nucleus and the cytoplasm showed a 
positive staining for HPGDS. Interestingly, 30 min after mast cell activation, only cytosolic 
staining around the nucleus was observed for HPGDS as shown in Fig.17j and l. A strong 
HPGDS-positive cytosolic, but very weak nuclear staining was observed 60 min post-activation 
(Fig. 17m, o). In the negative controls treated with mouse isotype IgGs specific binding of the 
secondary antibody was observed.  
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Figure 17: Intracellular localization of human mast cell HPGDS. Mast cell lipid droplets were induced 
by exogenous treatment with arachidonic acid complexed to BSA (250 µM final fatty acid concentration) 
for 18 hours. Localization of mast cell HPGDS was investigated by immunofluorescence staining. Mast 
cells were stained under resting and activated conditions at different time points (15, 30, and 60 min post-
activation). The primary HPGDS antibody was probed with Alexa Fluor® 594-conjugated Goat Anti-
Mouse IgG (red).  Lipid droplets (LD) were stained with BODIPY 493/503 (green) and nuclei were 
counterstained with DAPI (blue). Merged images are shown in the right-hand panels. Data with cells 
derived from one representative donor is shown 
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Finally, the protein expression of HPGDS was analyzed in human mast cells by Western blotting. A 
23 kDa immuno-reactive band, representing HPGDS, was detected in mast cells under resting and 
activated conditions (Fig 18). The expression of HPGDS was weak in resting cells, but clearly 
increased upon activation of the cells at all of the time points (Fig 18 lanes 1, 3-6, respectively).  
The level of HPGDS expression stayed the same over the entire period (up to 4 h after mast cell 
activation, lane 6). GAPDH was used as a loading control and displayed equal expression under 
both resting and activated conditions (Fig. 18 lower part).  
 
 
 
Figure 18: HPGDS protein in CD 34+ derived human mast cells. Total mast cell protein lysates were 
separated under reducing conditions by 12% SDS-PAGE, blotted onto nitrocellulose membrane and probed 
with mouse anti-human HPGDS (0.1 µg/ml). GAPDH was used as a loading control. Lanes: 1. CTRL, 2. IgE 
CTRL (3 h at +37° C), 3. αIgE 30 min, 4. αIgE 1 h, 5. αIgE 2 h, 6. αIgE 4 h. Data with cells derived from one 
representative donor is shown. 
 
37 kDa GAPDH  
Lanes 
HPGDS 
IgE/anti-IgE              -/-      +/-    +/+   +/+    +/+   +/+    
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5 Discussion 
 
First observations that mast cell lipid droplets might serve as sites of eicosanoid biosynthesis were 
published already in 1980s by Dvorak and co-workers, when they found large quantities of 
arachidonic acid in cytoplasmic lipid droplets of human lung mast cells.
23
 The research group came 
to the conclusion that this myriad of arachidonic acid in lipid droplets must have a critical function 
in mast cell biology. Later in 1992, an observation was published which demonstrated the presence 
of prostaglandin endoperoxide (PGH) synthase (cyclooxygenase) in lipid droplets of human lung 
mast cells.
45
 Another interesting observation was reported by Triggiani et al.
46
 who compared the 
total cellular content of arachidonic acid among different types of immune cells. They published 
that human lung mast cells had the highest arachidonic acid content with almost 50% of arachidonic 
acid being incorporated into neutral lipids, and that within the neutral lipids over 80% were found to 
be esterified into triglycerides. Altogether, these interesting findings support the idea that mast cell 
lipid droplets are cellular organelles in which lipid mediator generation may take place.   
 
In this study we focused on the role of ATGL and HSL in human mast cells as putative candidates 
for releasing arachidonic acid from triglycerides of lipid droplets for the generation of PGD2. 
Exogenous arachidonic acid has been shown to enhance lipid droplet formation in mast cells. 
29
 Our 
treatment of mast cell lipid droplets with 250 mmol of oleic acid for 18 to 20 hours  induced  the 
production of lipid droplets in mast cells  (Fig. 16b, c), which is in accordance with the previous 
finding that the presence of extracellular oleic acid accelerates the formation of lipid droplets.
29
     
According to our data, primary in vitro-generated mature mast cells are capable of releasing PGD2 
in culture when activated via IgE receptor cross-linking. A notable increase in PGD2 release after 
long term mast cell activation (Fig.7) was observed. Since AA-derived products are not stored but 
known to be synthesized de-novo, new enzyme molecules are likely to be synthesized in the mast 
cells during the activation since their production lasted up to 48 hours. On the other hand, these 
enzymes might be very stable with a long half-life. COX-2 is known to be degraded rapidly, 
whereas COX-1 and HPGDS are considered rather stable at least in megakaryocytes with “normal” 
intracellular levels of calcium.
20
 Long term release of AA-derived products also requires large 
amounts of arachidonic acid. Indeed, mast cell lipid droplets contain much of arachidonic acid 
esterified in triglycerides, which might be released by ATGL and/or HSL and further used for PGD2 
production.  Triglyceride -hydrolyzing lipase(s) able to respond to cell activation and to mobilize 
 45 
 
arachidonic acid producing PGD2 must be available in the droplet, if the lipid droplet actually is an 
immediate source for arachidonic acid. 
 
We analyzed the gene expression of these putative candidate lipases, ATGL and HSL, as well as the 
ATGL co-activating factor CGI-58, in resting and activated mast cells. We also analyzed the mRNA 
expression levels of the prostaglandin D synthase HPGDS, which is the major PGD2-forming 
enzyme in human mast cells
47
. According to our qPCR, Western blot and immunofluorescence data 
mast cells expressed HPGDS (Fig. 6f and 18).  A scientific article supporting this observation was 
published while the writing of this thesis was still in progress.
48
 In our experiments, the relative 
expression of HPGDS increased already in IgE treated mast cells compared to control treated cells 
and the expression was even greater in mast cells treated with αIgE also (Fig.18). Although the 
expression of HPGDS seems to be different in IgE-stimulated and unstimulated mast cells, this 
cannot be said for sure on the basis of one experiment and would require more detailed analysis. 
However our findings are supported by the previous finding that HPGDS can be up-regulated
5
 and 
induced by KIT in immature mouse bone marrow derived mast cells.
28,49
 An intracellular protein 
RasGRP4
2,5,8,49
 that regulates the expression of HPGDS gene,
49,50
 the presence on  DAG which has 
been shown to modify the RasGRP4- mediated effects on HPGDS gene expression;
2,5
  or MITF
50
 
that regulates the expression of Kit and specifically activates the cyclooxygenase pathway by 
binding to the HPGDS gene promoter region
50
 might also enhance the generation of PGD2 at least 
in mouse bone marrow mast cells.
2,50
 It is not known if  any other mast cell surface receptors, 
besides the IgE receptor, regulate the expression of HPGDS as well. 
 
No significant changes were observed in the mRNA expression levels of ATGL, HSL, CGI-58, 
HPGDS or COX-1 during mast cell activation (Fig. 6a-d, f). The only significant changes in mRNA 
expression levels were observed for COX-2 (Fig. 6e). Indeed, the expression level of this inducible 
cyclooxygenase increased more than 40-fold one hour after activation and after that the peak 
sharply declined. This is in accordance with the previous knowledge about the phasic response of 
the PGD2 release
11,13,28,50
 and the role of COX-2 as an inducible enzyme. The sudden decrease in 
COX-2 amount after 2 hours might result from a negative regulation mediated by a PGD2 
metabolite, the 15-deoxy- Δ 812,149-PGJ2, which would then also reduce the amount of PGD2 
released.
8
  Even though there were no changes in mRNA levels of ATGL and HSL and CGI-58 in 
activated mast cells, their enzymatic activities may have been changed
39
. The correlation between 
gene expression and protein levels depends on the cell type and experimental conditions, which 
may induce diverse changes in the regulation of mRNA and protein levels. Actually, the correlation 
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can be affected by changes in the degradation rate of mRNA, alternative splicing, protein stability 
and post translational modifications.
51
  Therefore, protein levels cannot be deduced straightforward 
from the changes in mRNA levels or vice versa. 
 
According to our immunofluorescence staining, both ATGL and HPGDS were recognized 
throughout the cytosolic area in the non-activated Ctrl cells, and hence the localization of ATGL in 
mast cells resembles that of the adipocytes
19
.  Although HPGDS located in the circumference of 
mast cells, no clear localization of HPGDS was observed in the circumference of mast cell lipid 
droplets. This would have been expected based on previous findings about the localizations of 
synthetic enzymes for leukotrienes and PGs within the lipid droplets
1
 or of COXs on the lipid 
droplet surface
23
. We do not know whether HPGDS even needs to be located on the lipid droplet 
surface, but visualization of HPGDS on the lipid droplet surface by confocal microscopic studies 
might provide an answer to this question. The use of confocal microscopy would be mandatory, 
since it is difficult to reveal any co-localization of HPGDS with lipid droplets by using normal 
fluorescence microscopy because the very strong HPGDS expression gives also a very strong signal 
when performing immunofluorescence staining. In order to establish the presence of HPGDS on 
lipid droplets, fractionation experiments to isolate pure lipid droplet fractions for testing the 
presence of HPGDS on lipid droplets by aid of Western blotting would also be needed. In the 
present work such lipid droplet isolation was not pursued, since it would have required large 
quantity of biological material and careful analysis using various organelle markers to exclude 
cross-contaminations. 
 
In order to study the possibility that the triglyceride -hydrolyzing lipase(s) ATGL and HSL are able 
to respond to cell activation and to mobilize arachidonic acid for PGD2 production in mast cells, 
siRNA transfection experiments were performed. Silencing the ATGL gene or HSL gene in human 
mast cells did not reveal any significant reduction of PGD2 release, when analyzing the release of 
this lipid mediator during the early phase (30 to 120 min after activation) of mast cell activation 
(Fig. 8, 12). The HSL single silencing somewhat reduced the amount of PGD2 produced in the early 
phase, but not significantly (Fig. 8).These observations are in contradiction with a latter study 
conducted at the Wihuri Research Institute, in which ATGL single silencing was observed to reduce 
the amount of eicosanoids produced.
52
 As a consequence, we also included analysis of a shorter 
time point, just in case the reduction in PGD2 levels had occurred faster and already happened 
during the acute phase of activation, i.e. during the time period spanning from the moment of 
activation until 15 minutes after the activation. We studied the effect of HSL and ATGL single and 
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double silencing during the acute PGD2 release, and surprisingly, could observe a clear reduction in 
PGD2 levels compared to control-silenced mast cells (Fig 13). HSL knockdown showed a clear 
reduction (60% of control cells after 5 minutes and 70% after 15 minutes) in PGD2 release in acute 
phase compared to control cells, and in ATGL single-silenced mast cells the reduction was even 
more pronounced (27% after 5 minutes and 48% after 15 minutes) probably because ATGL 
catalyzes the rate limiting step of triglyceride hydrolysis. By far the strongest reduction in the acute 
PGD2 release was seen with the ATGL+HSL –double knockdown, likely because both enzymes are 
able to start hydrolyzing triglycerides. The release was 17% of that of the controls after 5 minutes 
and 37% after 15 minutes. ATGL and HSL are probable candidates for mobilizing arachidonic acid 
from triglycerides in mast cell lipid droplets for the use in biosynthesis of PGD2 since knockdown 
of these two enzymes cuts down the release of PGD2. Another possible fate of the arachidonic acid 
released from triglycerides is the lipid droplet monolayer, where arachidonic acid might get re-
esterified into phospholipids, and then released again by the action of phospholipases.
53
  
 
The challenges for the generation of primary mast cells from circulating progenitor cells derived 
from adult peripheral blood include donor variability and accessibility, the possibility of 
contamination with other cell types and microbiological organisms, compromised mast cell survival 
and growth in culture, and finally, also variation in the transfection efficiency. The ATGL and HSL 
knockdowns were successful as judged by reduced transcript levels in qPCR. However, these 
knockdowns were not strong enough to cut down the early phase of PGD2 production. Despite this 
failure, we propose that HSL and ATGL might be the ones mainly affecting the amount of PGD2 
released from activated mast cells in the acute and early phase of PGD2 release, but that also some 
other factors likely play a role. The ramifications of this study include the possibility that 
arachidonic acid release from triglycerides for the formation of eicosanoids could take an indirect or 
a direct route to supply precursors for cellular eicosanoid biosynthesis (Fig. 19; left and right, 
respectively).  
 
The proposed indirect pathway in mast cells could involve release of PGD2 through a more 
regulated pathway (Fig. 19, on the left-hand side). In this indirect pathway, arachidonic acid is 
released from triglycerides present in the lipid droplets by ATGL and/or HSL, then activated by 
ACSL3 or ACSL4 and included into lipid droplet membrane phospholipids (PLs). cPLA could 
release this incorporated arachidonic acid which could be then converted to PGH for lipid mediator 
generation by the COX-1 enzyme whose expression stays up until the onset of mast cell activation. 
Phospholipase A2- family consist of 15 different isoenzymes, which all enzymatically hydrolyze sn-
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2 -ester bonds of glycerophospholipids releasing fatty acids (AA) and lysophospholipids 
(lysophosphatidylcholine, LPC). cPLA2 is a multi-compartment enzyme whose function as a major 
arachidonic acid  releasing enzyme is well established.
35,37,39
 It is not so long ago that arachidonic 
acid  released from phospholipids of various membranous structures by cPLA was held as the only 
substrate for eicosanoid biosynthesis.
33
 The experiments carried out at the Wihuri Research 
Institute, including those presented here, have established that, in addition to phospholipids, the 
triglycerides present in mast cell lipid droplet core also are an important source of eicosanoids, and 
that also ATGL and HSL, not just cPLA, can release arachidonic acid for eicosanoid production.  
 
 
 
Figure 19: Acute and short term release of PGD2 from TG-derived AA stored in human MC LDs. 
Human mast cells could release PGD2 from triglyceride-derived arachidonic acid stored in human mast cell 
lipid droplets via direct or indirect pathways. In the direct pathway (on the right), arachidonic acid is released 
by ATGL or HSL from lipid droplet triglycerides and this free arachidonic acid is used by COX-1 or COX-2 
depending on the status of the cell for the generation of prostaglandins. In the indirect pathway (on the left-
hand side), arachidonic acid is liberated from lipid droplet triglycerides by ATGL or HSL and then further re-
esterified into phospholipids from where arachidonic acid can then finally be released by cPLA2 for the 
generation of eicosanoids. Abbreviations: ATGL = adipose triglyceride lipase, HSL = hormone-sensitive 
lipase, ACSL = long chain acyl-CoA synthetase, cPLA2 = cytosolic phospholipase A2, COX = 
cyclooxygenase 1 and 2, HPGDS = hematopoietic prostaglandin D synthase, AA = arachidonic acid, PGH = 
prostaglandin H, PGD2 = prostaglandin D2, TG = triglyceride, AA = arachidonic acid, MC = mast cell, LD = 
lipid droplet. Figure modified from Dichlberger et al.
52
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Under conditions of immunological mast cell stimulation (Fig. 4), the arachidonic acid present in 
the lipid droplets could be released from triglycerides via a direct pathway (Fig. 19; on the right-
hand side). In the proposed direct pathway arachidonic acid is released from the triglycerides 
present in the lipid droplets of mast cells by CGI-58-activated ATGL and HSL and the free 
arachidonic acid is then converted to PGH by either COX-1 under basal conditions and/or COX-2 
under activated conditions. This presumption is supported by the fact that the basal and immediate 
PGD2 release is mediated by COX-1 which is also constitutively expressed in mast cells (Fig. 6d).
24
 
Incubation of the constitutively expressed COX-1 with aspirin has been shown to irreversibly 
inhibit the release of PGD2 during the first 30 minutes after mast cell activation.
52
 This enzyme is 
believed to be responsible for the immediate phase of the eicosanoid release in unstimulated mast 
cells, while COX-2 is believed to be responsible for the delayed and stimulated phase of PGD2 
release.
13,24,52
 The second, delayed but pronounced phase of PGD2 generation was visibly affected 
by ATGL and HSL knockdowns in a reducing manner. This phase of PGD2 generation is likely 
elicited by KIT and certain interleukins, is regulated by exogenous factors controlling the 
expression levels of COXs and by the availability of cytokines,
11
 requires mast cell sensitization 
with IgE and is mediated by and dependent on COX-2
13,24
 (Fig. 19, on the right-hand side), the gene 
expression of which was highly up-regulated as late as after 1 hour of activation (Fig. 6e). However, 
the effect of KIT on COX-2 induction and expression is somewhat controversial.
13,28,50
 Moreover, in 
some studies the KIT-stimulated increase in the expression of cPLA2, COX-1 and HPGDS have 
been shown to lead to a selective increase in IgE-dependent production of PGD2 from endogenous 
arachidonic acid.
28
  
 
Regardless of the pathway of releasing arachidonic acid -either directly from triglycerides for the 
generation of eicosanoids or indirectly via the phospholipids, HPGDS could convert the PGH into 
PGD2 which in turn would be released from the lipid droplet into the mast cell cytosol. It has been 
reported that mice having a disrupted HPGDS gene are unable to produce PGD2 both during the 
acute and delayed phases.
50
 Since both phases of PGD2 production depend on HPGDS, the enzyme 
likely plays its role(s) at the intersection of the direct and indirect pathways of arachidonic acid 
liberation and PGD2 production from both the triglyceride core and the phospholipid monolayer of 
the mast cell lipid droplet.  In accordance with this presumption is the finding that the amount of 
PGD2 produced is determined mainly by the amount of HPGDS in the cell while KIT also in some 
way regulates the amount and expression of HPGDS.
49
 IL-3 also has minor effects on HPGDS 
levels.
49
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6 Closing words 
 
Prostaglandin levels are generally low in non-inflamed tissues, but during inflammation, the levels 
and the molecular profiles of the prostaglandins produced changes markedly.
21
  Indeed, 
prostaglandins have been found to be important both in the acute phase and the resolution phase of 
inflammation.
11
 Acute inflammation begins with the production of soluble mediators by the cells 
residing in the injured or infected tissue.
14
 The cells include mast cells that contribute to the 
inflammation by releasing both preformed mediators such as histamine and newly formed 
mediators, such as the eicosanoids.
13,14
 Different eicosanoids derived from arachidonic acid can 
either alleviate or worsen the inflammatory responses and influence the magnitude, nature and 
duration of the immune responses. Even the same eicosanoid produced by either COX-1 or COX-2 
may in different situations promote or help resolve the inflammation.
11,21
  
 
PGD2 production by mast cells initiates IgE-mediated allergic responses in the body
21
 by acting as a 
local mediator in an autocrine and paracrine fashion. The presence of an allergic antigen can induce 
the production PGD2 in sensitized individuals; for example, in patients suffering from allergic 
asthma, PGD2 released by pulmonary mast cells can be detected from bronchoalveolar lavage fluid 
during an asthma attack.
21,49
  PGD2 causes a contraction of the bronchial airways, and because of 
the strong mechanistic link of such contraction to the pathogenesis of this disease, several drugs that 
seek to reduce PGD2 levels in asthma have  already been tested in clinical trials.  
 
PGD2 may also play a role in the evolution of atherosclerosis.
21
 In the inflamed arterial intima of an 
atherosclerotic arterial segment, the amount of PGD2 increases because inflammatory cells 
producing HPGDS show positive chemotaxis and permeate the vasculature.
21
   The expression and 
presence of ATGL in human mast cells and its importance for the generation of PGD2 from mast 
cell lipid droplets has by now been published from Wihuri Research Institute, 
52
 while the presence 
of CGI-58 is so far an unpublished observation. In addition to ATGL and HSL, also other enzymes 
likely are important for the triglyceride lipolysis, fat physiology and eicosanoid biosynthesis –
especially for the generation of PGD2 in mast cells. Based on their newly discovered roles in 
inflammation, ATGL and HSL might even be potential targets for new drugs. However, since they 
are widely distributed in the human body, notably having physiological roles in the adipose tissue, a 
tissue-targeted or a cell-targeted approach might be necessary to selectively influence their 
functions in pathophysiologically relevant pathways. Even without any direct clinical benefits, basic 
research on these triglyceride lipases helps figuring out the mechanism and pathways of eicosanoid 
biosynthesis in mast cells and other inflammatory cells, and thereby widens our understanding 
 51 
 
about the pathways leading to the PGD2 synthesis and the progressions of inflammatory diseases, 
such as asthma and atherosclerosis. 
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10 Attachments 
 
Attachment 1: Weekly plan for mast cell maintaining. 
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